The complexity of finding fit-for-purpose real-world data for oncology patients with rare NTRK gene fusions and a novel solution
The rarity of patients with <i>NTRK</i> gene fusion-positive cancer and number of eligible CGDBs/clinical sites present challenges for the identification of sufficient RWD sources that can be used in comparative effectiveness studies to contextualize results from single-arm trials. This approach provides a potential solution to identify fit-for-purpose RWD to support precision medicine for patients with cancer harboring rare genomic alterations.
Authors
- Vadim Bernard-Gauthier
- M Bassel (ORCID: https://orcid.org/0009-0007-9726-7930)
- Barbara Lennert
- Amanda Bruno (ORCID: https://orcid.org/0009-0007-6721-2234)
- Neil R. Brett (ORCID: https://orcid.org/0000-0002-6175-2535)
- Xinliang Pan
- M S Pollack
- Jihong Zong
- X. Jiao (ORCID: https://orcid.org/0000-0001-6550-8321)
Institutions
- Bayer (United States) (US)
- Thermo Fisher Scientific (Canada) (CA)
- Bayer (Canada) (CA)
- Macula Vision Research Foundation (US)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100139
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer Corporation